Chemotherapy agent-unsaturated fatty acid prodrugs and prodrug-nanoplatforms for cancer chemotherapy

被引：135
作者：
Sun, Bingjun [1 ]
Luo, Cong [1 ]
Cui, Weiping [1 ]
Sun, Jin [1 ,2 ]
He, Zhonggui [1 ]
机构：
[1] Shenyang Pharmaceut Univ, Sch Pharm, Dept Pharmaceut, 59 Mailbox,103 Wenhua Rd, Shenyang 110016, Liaoning, Peoples R China
[2] Shenyang Pharmaceut Univ, Sch Pharm, Municipal Key Lab Biopharmaceut, Shenyang 110016, Liaoning, Peoples R China
来源：
JOURNAL OF CONTROLLED RELEASE | 2017年 / 264卷
基金：
中国国家自然科学基金;
关键词：
Cancer therapy; Unsaturated fatty acids; Prodrugs; Prodrug-based nano-DDS; CONJUGATED LINOLEIC-ACID; DHA-PACLITAXEL TAXOPREXIN; CHOLESTEROL-RICH EMULSION; NUCLEOSIDE TRANSPORTER 1; LIPID VECTOR TECHNOLOGY; TARGETED DRUG-DELIVERY; PHASE-2; OPEN-LABEL; TUMOR-CELL LINES; II OPEN-LABEL; DOCOSAHEXAENOIC ACID;
D O I：
10.1016/j.jconrel.2017.08.034
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Unsaturated fatty acids (UFAs), with the distinct advantages of good biocompatibility and innate tumor-targeting effect, have been widely investigated for the rational design of chemotherapy agent-unsaturated fatty acid (CA-UFA) prodrugs in cancer therapy. Among them, several CA-UFA prodrugs have successfully entered clinical trials and are promising prospects for potential clinical applications. In addition, CA-UFA prodrug-based nanoparticulate drug delivery systems (nano-DDS), which integrate the advantages of CA-UFA prodrugs and nano-DDS, have been emerging as versatile nano-carriers for the efficient delivery of chemotherapeutics. In this paper, we review the advanced drug delivery strategies based on UFA conjugates and focus on the recent advances in CA-UFA prodrugs and the emerging CA-UFA prodrug-based nano-DDS. First, we discuss the rational design of CA-UFA prodrugs in response to the multiple obstacles in chemotherapy, with particular emphasis on the latest progress in both preclinical studies and clinical trials. Moreover, the emerging CA-UFA prodrug-based nano-DDS are also addressed. Finally, the prospects and potential challenges of CA-UFA prodrug-based drug delivery strategies in chemotherapy are highlighted.
引用
收藏
页码：145 / 159
页数：15
相关论文
共 148 条
[1]   Anti proliferative activity of ELACYT™ (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells [J].
Adams, David J. ;
Sandvold, Marit L. ;
Myhren, Finn ;
Jacobsen, Tove F. ;
Giles, Frank ;
Rizzieri, David A. .
LEUKEMIA & LYMPHOMA, 2008, 49 (04) :786-797
[2]   Induction of Resistance to the Lipophilic Cytarabine Prodrug Elacytarabine (CP-4055) in CEM Leukemic Cells [J].
Adema, A. D. ;
Losekoot, N. ;
Smid, K. ;
Kathmann, I. ;
Myhren, F. ;
Sandvold, M. L. ;
Peters, G. J. .
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2010, 29 (4-6) :394-399
[3]   Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel [J].
Adema, A. D. ;
Laan, A. C. ;
Myhren, F. ;
Fichtner, I. ;
Verheul, H. M. ;
Sandvold, M. L. ;
Peters, G. J. .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2010, 36 (01) :285-294
[4]   Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126 [J].
Adema, Auke D. ;
Smid, Kees ;
Losekoot, Nienke ;
Honeywell, Richard J. ;
Verheul, Henk M. ;
Myhren, Finn ;
Sandvold, Marit L. ;
Peters, Godefridus J. .
INVESTIGATIONAL NEW DRUGS, 2012, 30 (05) :1908-1916
[5]   Uptake of a cholesterol-rich emulsion by neoplastic ovarian tissues [J].
Ades, A ;
Carvalho, JP ;
Graziani, SR ;
Amancio, RF ;
Souen, JS ;
Pinotti, JA ;
Maranhao, RC .
GYNECOLOGIC ONCOLOGY, 2001, 82 (01) :84-87
[6]  
[Anonymous], ADV DRUG DELIV REV
[7]   Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates [J].
Ansell, Steven M. ;
Johnstone, Sharon A. ;
Tardi, Paul G. ;
Lo, Lily ;
Xie, Sherwin ;
Shu, Yu ;
Harasym, Troy O. ;
Harasym, Natashia L. ;
Williams, Laura ;
Bermudes, David ;
Liboiron, Barry D. ;
Saad, Walid ;
Prud'homme, Robert K. ;
Mayer, Lawrence D. .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (11) :3288-3296
[8]   Nanotechnology in cancer therapy [J].
Aslan, Burcu ;
Ozpolat, Bulent ;
Sood, Anil K. ;
Lopez-Berestein, Gabriel .
JOURNAL OF DRUG TARGETING, 2013, 21 (10) :904-913
[9]   Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma [J].
Bedikian, A. Y. ;
DeConti, R. C. ;
Conry, R. ;
Agarwala, S. ;
Papadopoulos, N. ;
Kim, K. B. ;
Ernstoff, M. .
ANNALS OF ONCOLOGY, 2011, 22 (04) :787-793
[10]   α-Synuclein and Polyunsaturated Fatty Acids Promote Clathrin-Mediated Endocytosis and Synaptic Vesicle Recycling [J].
Ben Gedalya, Tziona ;
Loeb, Virginie ;
Israeli, Eitan ;
Altschuler, Yoram ;
Selkoe, Dennis J. ;
Sharon, Ronit .
TRAFFIC, 2009, 10 (02) :218-234
12345678910